<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04087187</url>
  </required_header>
  <id_info>
    <org_study_id>D7550C00009</org_study_id>
    <nct_id>NCT04087187</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Drug Absorption Into the Blood After Administration of 3 Doses of AZD5718</brief_title>
  <official_title>A Randomized, 3-period, 3-treatment, Single-dose, Open-label, Single-center, Crossover Study to Assess the Pharmacokinetics of 3 Doses of AZD5718</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Parexel</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be conducted to evaluate the AZD5718 pharmacokinetic (PK) doses in order to&#xD;
      determine exposure in a new dose range and compare with previous results. This study will&#xD;
      include 14 subjects in a single site in United Kingdom. Each subject will be involved in the&#xD;
      study for 6 to 7 weeks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be an open-label, randomized, 3-period, 3-treatment, crossover study&#xD;
      performed in healthy subjects at a single study center.&#xD;
&#xD;
      A total of 14 healthy male and female subjects (of no childbearing potential) will be&#xD;
      randomized to ensure that at least 12 subjects are evaluable. Each subject will receive 3&#xD;
      different treatments at least 4 days apart and will be dosed following an overnight fast of&#xD;
      at least 10 hours. The following treatments will be given:&#xD;
&#xD;
        -  Treatment A: AZD5718 Dose A tablet&#xD;
&#xD;
        -  Treatment B: AZD5718 Dose B tablet&#xD;
&#xD;
        -  Treatment C: AZD5718 Dose C tablet&#xD;
&#xD;
      The study will comprise:&#xD;
&#xD;
        -  A Screening Period of maximum 28 days.&#xD;
&#xD;
        -  Three Treatment Periods during which subjects will be resident from the day before first&#xD;
           dosing with AZD5718 (Day -1) in Treatment Period 1 until at least 48 hours after last&#xD;
           dosing with AZD5718 in Treatment Period 3 for collection of PK and safety samples.&#xD;
           Subjects will be discharged on Day 3 of Treatment Period 3.&#xD;
&#xD;
        -  A Follow up Visit, 5 to 7 days after the last dose of investigational medicinal product&#xD;
           (IMP).&#xD;
&#xD;
      There will be a minimum washout period of 4 days between each dose administration.&#xD;
&#xD;
      Each subject will be involved in the study for 6 to 7 weeks. This study will be conducted in&#xD;
      male and female subjects aged 18 to 55 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 20, 2019</start_date>
  <completion_date type="Actual">October 31, 2019</completion_date>
  <primary_completion_date type="Actual">October 31, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>The following treatments will be given in crossover design:&#xD;
Treatment A: AZD5718 Dose A tablet&#xD;
Treatment B: AZD5718 Dose B tablet&#xD;
Treatment C: AZD5718 Dose C tablet&#xD;
There will be 6 arms consisting of all possible treatment sequences. The treatment sequence per arm will be:&#xD;
Arm1: ABC Arm2: ACB Arm3: BAC Arm4: BCA Arm5: CAB Arm6: CBA</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic parameter: Area under plasma concentration time curve from zero to infinity (AUC)</measure>
    <time_frame>Day 1: Pre dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12 and 18 hours post dose, Day 2: 24 and 36 hours post dose and Day 3: 48 hours post dose</time_frame>
    <description>To evaluate the pharmacokinetics and exposure of 3 different doses of AZD5718</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameter: Area under the plasma concentration curve from time zero to time of last quantifiable concentration (AUClast)</measure>
    <time_frame>Day 1: Pre dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12 and 18 hours post dose, Day 2: 24 and 36 hours post dose and Day 3: 48 hours post dose</time_frame>
    <description>To evaluate the pharmacokinetics and exposure of 3 different doses of AZD5718</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameter: Maximum observed plasma concentration (Cmax)</measure>
    <time_frame>Day 1: Pre dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12 and 18 hours post dose, Day 2: 24 and 36 hours post dose and Day 3: 48 hours post dose</time_frame>
    <description>To evaluate the pharmacokinetics and exposure of 3 different doses of AZD5718</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameter: Drug concentration 24 hours after dosing (C24)</measure>
    <time_frame>Day 1: Pre dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12 and 18 hours post dose, Day 2: 24 and 36 hours post dose and Day 3: 48 hours post dose</time_frame>
    <description>To evaluate the pharmacokinetics and exposure of 3 different doses of AZD5718</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameter: Half life associated with terminal slope (λz) of a semi logarithmic concentration time curve (t1/2λz)</measure>
    <time_frame>Day 1: Pre dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12 and 18 hours post dose, Day 2: 24 and 36 hours post dose and Day 3: 48 hours post dose</time_frame>
    <description>To evaluate the pharmacokinetics and exposure of 3 different doses of AZD5718</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameter: Time to reach maximum observed plasma concentration (tmax)</measure>
    <time_frame>Day 1: Pre dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12 and 18 hours post dose, Day 2: 24 and 36 hours post dose and Day 3: 48 hours post dose</time_frame>
    <description>To evaluate the pharmacokinetics and exposure of 3 different doses of AZD5718</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameter: Apparent total body clearance of drug from plasma after extravascular administration (CL/F)</measure>
    <time_frame>Day 1: Pre dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12 and 18 hours post dose, Day 2: 24 and 36 hours post dose and Day 3: 48 hours post dose</time_frame>
    <description>To evaluate the pharmacokinetics and exposure of 3 different doses of AZD5718</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with advers event</measure>
    <time_frame>Upto 7 weeks</time_frame>
    <description>Number of subjects with adverse event and/or abnormal vital signs or physical examination or laboratory assessments to further assess the safety of single doses of AZD5718 in healthy subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameter: AUC</measure>
    <time_frame>Day 1: Pre dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12 and 18 hours post dose, Day 2: 24 and 36 hours post dose and Day 3: 48 hours post dose</time_frame>
    <description>To assess dose proportionality of AZD5718</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameter: Cmax</measure>
    <time_frame>Day 1: Pre dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12 and 18 hours post dose, Day 2: 24 and 36 hours post dose and Day 3: 48 hours post dose</time_frame>
    <description>To assess dose proportionality of AZD5718</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Arm1: AZD5718 Dose A + AZD5718 Dose B + AZD5718 Dose C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive one tablet once daily (QD) of each treatment according to treatment arm.&#xD;
Treatment A: AZD5718 Dose A, Treatment B: AZD5718 Dose B, Treatment C: AZD5718 Dose C, with a minimum washout period of 4 days between each dose administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm2: AZD5718 Dose A + AZD5718 Dose C + AZD5718 Dose B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive one tablet once daily (QD) of each treatment according to treatment arm.&#xD;
Treatment A: AZD5718 Dose A, Treatment C: AZD5718 Dose C, Treatment B: AZD5718 Dose B, with a minimum washout period of 4 days between each dose administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm3: AZD5718 Dose B + AZD5718 Dose A + AZD5718 Dose C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive one tablet once daily (QD) of each treatment according to treatment arm.&#xD;
Treatment B: AZD5718 Dose B, Treatment A: AZD5718 Dose A, Treatment C: AZD5718 Dose C, with a minimum washout period of 4 days between each dose administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm4: AZD5718 Dose B + AZD5718 Dose C + AZD5718 Dose A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive one tablet once daily (QD) of each treatment according to treatment arm.&#xD;
Treatment B: AZD5718 Dose B, Treatment C: AZD5718 Dose C, Treatment A: AZD5718 Dose A, with a minimum washout period of 4 days between each dose administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm5: AZD5718 Dose C + AZD5718 Dose A + AZD5718 Dose B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive one tablet once daily (QD) of each treatment according to treatment arm.&#xD;
Treatment C: AZD5718 Dose C, Treatment A: AZD5718 Dose A, Treatment B: AZD5718 Dose B, with a minimum washout period of 4 days between each dose administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm6: AZD5718 Dose C + AZD5718 Dose B + AZD5718 Dose A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive one tablet once daily (QD) of each treatment according to treatment arm.&#xD;
Treatment C: AZD5718 Dose C, Treatment B: AZD5718 Dose B, Treatment A: AZD5718 Dose A, with a minimum washout period of 4 days between each dose administration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment A</intervention_name>
    <description>Subject will be given AZD5718 Dose A tablet once daily</description>
    <arm_group_label>Arm1: AZD5718 Dose A + AZD5718 Dose B + AZD5718 Dose C</arm_group_label>
    <arm_group_label>Arm2: AZD5718 Dose A + AZD5718 Dose C + AZD5718 Dose B</arm_group_label>
    <arm_group_label>Arm3: AZD5718 Dose B + AZD5718 Dose A + AZD5718 Dose C</arm_group_label>
    <arm_group_label>Arm4: AZD5718 Dose B + AZD5718 Dose C + AZD5718 Dose A</arm_group_label>
    <arm_group_label>Arm5: AZD5718 Dose C + AZD5718 Dose A + AZD5718 Dose B</arm_group_label>
    <arm_group_label>Arm6: AZD5718 Dose C + AZD5718 Dose B + AZD5718 Dose A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment B</intervention_name>
    <description>Subjects will be given AZD5718 Dose B tablet once daily</description>
    <arm_group_label>Arm1: AZD5718 Dose A + AZD5718 Dose B + AZD5718 Dose C</arm_group_label>
    <arm_group_label>Arm2: AZD5718 Dose A + AZD5718 Dose C + AZD5718 Dose B</arm_group_label>
    <arm_group_label>Arm3: AZD5718 Dose B + AZD5718 Dose A + AZD5718 Dose C</arm_group_label>
    <arm_group_label>Arm4: AZD5718 Dose B + AZD5718 Dose C + AZD5718 Dose A</arm_group_label>
    <arm_group_label>Arm5: AZD5718 Dose C + AZD5718 Dose A + AZD5718 Dose B</arm_group_label>
    <arm_group_label>Arm6: AZD5718 Dose C + AZD5718 Dose B + AZD5718 Dose A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment C</intervention_name>
    <description>Subjects will be given AZD5718 Dose C tablet once daily</description>
    <arm_group_label>Arm1: AZD5718 Dose A + AZD5718 Dose B + AZD5718 Dose C</arm_group_label>
    <arm_group_label>Arm2: AZD5718 Dose A + AZD5718 Dose C + AZD5718 Dose B</arm_group_label>
    <arm_group_label>Arm3: AZD5718 Dose B + AZD5718 Dose A + AZD5718 Dose C</arm_group_label>
    <arm_group_label>Arm4: AZD5718 Dose B + AZD5718 Dose C + AZD5718 Dose A</arm_group_label>
    <arm_group_label>Arm5: AZD5718 Dose C + AZD5718 Dose A + AZD5718 Dose B</arm_group_label>
    <arm_group_label>Arm6: AZD5718 Dose C + AZD5718 Dose B + AZD5718 Dose A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provision of signed and dated, written informed consent prior to any study specific&#xD;
             procedures.&#xD;
&#xD;
          -  Healthy male and/or female subjects aged 18 to 55 years (inclusive at Screening Visit)&#xD;
             with suitable veins for cannulation or repeated venipuncture.&#xD;
&#xD;
          -  Males must be willing to use appropriate contraception methods.&#xD;
&#xD;
          -  Females must have a negative pregnancy test at the Screening Visit and on admission to&#xD;
             the Clinical Unit (Day -1) must not be lactating and must be of non-childbearing&#xD;
             potential, confirmed at the Screening Visit by fulfilling one of the following&#xD;
             criteria&#xD;
&#xD;
               -  Postmenopausal defined as amenorrhea for at least 12 months or more following&#xD;
                  cessation of all exogenous hormonal treatments and follicle-stimulating hormone&#xD;
                  (FSH) levels in the postmenopausal range.&#xD;
&#xD;
               -  Documentation of irreversible surgical sterilization by hysterectomy, bilateral&#xD;
                  oophorectomy or bilateral salpingectomy but not tubal ligation.&#xD;
&#xD;
               -  Have a body mass index (BMI) between 18 and 30 kg/m2 inclusive and weigh at least&#xD;
                  50 kg and no more than 100 kg inclusive.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of any clinically significant disease or disorder which, in the opinion of the&#xD;
             Investigator, may either put the volunteer at risk because of participation in the&#xD;
             study, or influence the results or the volunteer's ability to participate in the&#xD;
             study.&#xD;
&#xD;
          -  History or presence of gastrointestinal (GI), hepatic or renal disease, or any other&#xD;
             condition known to interfere with absorption, distribution, metabolism, or excretion&#xD;
             of drugs.&#xD;
&#xD;
          -  Any clinically significant illness, medical/surgical procedure, or trauma within 4&#xD;
             weeks of the first administration of IMP.&#xD;
&#xD;
          -  Any clinically significant abnormalities in clinical chemistry, hematology, or&#xD;
             urinalysis results at the Screening Visit and/or admission to the Clinical Unit (Day&#xD;
             -1), as judged by the Investigator including:&#xD;
&#xD;
               -  Alanine aminotransferase (ALT) &gt;1.5 x upper limit of normal (ULN).&#xD;
&#xD;
               -  Aspartate aminotransferase (AST) &gt;1.5 x ULN.&#xD;
&#xD;
               -  Bilirubin (total) &gt;1.5 x ULN.&#xD;
&#xD;
               -  Gamma glutamyl transpeptidase (GGT) &gt;1.5 x ULN.&#xD;
&#xD;
          -  Any clinically significant abnormal findings in vital signs at the Screening Visit&#xD;
             and/or admission to the Clinical Unit (Day -1), as judged by the Investigator.&#xD;
&#xD;
          -  Any clinically significant abnormalities on 12 lead ECG at the Screening Visit, as&#xD;
             judged by the Investigator.&#xD;
&#xD;
          -  Any positive result on screening for serum hepatitis B surface antigen, hepatitis C&#xD;
             antibody, and human immunodeficiency virus (HIV) antibody.&#xD;
&#xD;
          -  Known or suspected history of drug abuse, as judged by the Investigator.&#xD;
&#xD;
          -  Known or suspected Gilbert's syndrome.&#xD;
&#xD;
          -  Known or suspected history of alcohol or drug abuse or excessive intake of alcohol as&#xD;
             judged by the Investigator.&#xD;
&#xD;
          -  Has received another new chemical entity (defined as a compound which has not been&#xD;
             approved for marketing) within 3 months of the 3 administration of IMP in this study.&#xD;
             The period of exclusion begins 3 months after the final dose or one month after the&#xD;
             last visit whichever is the longest. Note: subjects consented and screened, but not&#xD;
             randomized in this study or a previous Phase I study, are not excluded.&#xD;
&#xD;
          -  Plasma donation within 1 month of the Screening Visit or any blood donation/loss more&#xD;
             than 500 mL during the 3 months prior to the Screening Visit.&#xD;
&#xD;
          -  History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as&#xD;
             judged by the Investigator or history of hypersensitivity to drugs with a similar&#xD;
             chemical structure or class to AZD5718.&#xD;
&#xD;
          -  Current smokers or those who have smoked or used nicotine products (including&#xD;
             e-cigarettes) within the 3 months prior to the Screening Visit.&#xD;
&#xD;
          -  Excessive intake of caffeine containing drinks or food (eg, coffee, tea, chocolate,)&#xD;
             as judged by the Investigator.&#xD;
&#xD;
          -  Positive screen for drugs of abuse, alcohol or cotinine at the Screening Visit or on&#xD;
             admission to the Clinical Unit.&#xD;
&#xD;
          -  Use of drugs with enzyme-inducing properties such as St John's Wort within 3 weeks&#xD;
             prior to the first administration of IMP.&#xD;
&#xD;
          -  Use of any prescribed or non-prescribed medication including antacids, analgesics&#xD;
             (other than paracetamol/acetaminophen), herbal remedies, megadose vitamins (intake of&#xD;
             20 to 600 times the recommended daily dose) and minerals during the 2 weeks prior to&#xD;
             the first administration of IMP or longer if the medication has a long half-life.&#xD;
&#xD;
          -  Involvement of any AstraZeneca, PAREXEL or study site employee or their close&#xD;
             relatives.&#xD;
&#xD;
          -  Subjects who have previously received AZD5718.&#xD;
&#xD;
          -  Judgment by the Investigator that the subject should not participate in the study if&#xD;
             they have any ongoing or recent (ie, during the screening period) minor medical&#xD;
             complaints that may interfere with the interpretation of study data or are considered&#xD;
             unlikely to comply with study procedures, restrictions, and requirements.&#xD;
&#xD;
          -  Vulnerable subjects, eg, kept in detention, protected adults under guardianship,&#xD;
             trusteeship, or committed to an institution by governmental or juridical order.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <zip>HA1 3UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>August 19, 2019</study_first_submitted>
  <study_first_submitted_qc>September 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 12, 2019</study_first_posted>
  <last_update_submitted>November 14, 2019</last_update_submitted>
  <last_update_submitted_qc>November 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

